These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2362794)

  • 41. Hyperfractionation as an altered fractionation regimen in primary radiotherapy for squamous cell carcinoma of the larynx.
    Krstevska V; Smichkoska S
    Prilozi; 2006 Dec; 27(2):175-87. PubMed ID: 17211301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyperfractionated radiotherapy for T2 glottic cancer for preservation of the larynx.
    Tateya I; Hirano S; Kojima H; Omori K; Shoji K; Mitsumori M; Nagata Y; Ito J
    Eur Arch Otorhinolaryngol; 2006 Feb; 263(2):144-8. PubMed ID: 16012862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A clinical study of 1079 patients with laryngeal cancer].
    Fujii T; Sato T; Yoshino K; Inakami K; Nagahara M; Okita J
    Nihon Jibiinkoka Gakkai Kaiho; 1997 Aug; 100(8):856-63. PubMed ID: 9293766
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of radiotherapy on laryngeal cancer survival: a population-based study of 13,808 US patients.
    Zhang H; Travis LB; Chen R; Hyrien O; Milano MT; Newlands SD; Chen Y
    Cancer; 2012 Mar; 118(5):1276-87. PubMed ID: 21773970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term follow-up and pattern of failure for T1-T2 glottic cancer after definitive radiation therapy.
    Mourad WF; Hu KS; Shourbaji RA; Woode R; Harrison LB
    Am J Clin Oncol; 2013 Dec; 36(6):580-3. PubMed ID: 22868239
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conventional fractionation should not be the standard of care for T2 glottic cancer.
    Dixon LM; Douglas CM; Shaukat SI; Garcez K; Lee LW; Sykes AJ; Thomson D; Slevin NJ
    Radiat Oncol; 2017 Nov; 12(1):178. PubMed ID: 29137654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Long-term results and cause of failure analysis in larynx cancer patients irradiated conventionally and with accelerated fractionation schedules in 1995-1998].
    Szutkowski Z; Kawecki A; Jarząbski A
    Otolaryngol Pol; 2014; 68(6):320-7. PubMed ID: 25441938
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postoperative Radiotherapy Omitting Level Ⅳ for Locally Advanced Supraglottic and Glottic Laryngeal Carcinoma.
    Wu Y; Zhang L; Tang T; Li L; Li L; Yu H
    Technol Cancer Res Treat; 2021; 20():1533033820985876. PubMed ID: 33517858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical study of early laryngeal cancer].
    Nagatani G; Mori T; Udaka T; Shiomori T; Ohbuchi T; Suzuki H
    Nihon Jibiinkoka Gakkai Kaiho; 2007 Jun; 110(6):447-52. PubMed ID: 17633113
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiotherapy in T1 laryngeal cancer: prognostic factors for locoregional control and survival, uni- and multivariate analysis.
    Terhaard CH; Snippe K; Ravasz LA; van der Tweel I; Hordijk GJ
    Int J Radiat Oncol Biol Phys; 1991 Oct; 21(5):1179-86. PubMed ID: 1938516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary radiotherapy of T1 squamous cell carcinoma of the larynx: analysis of 478 patients treated from 1963 to 1985.
    Johansen LV; Overgaard J; Hjelm-Hansen M; Gadeberg CC
    Int J Radiat Oncol Biol Phys; 1990 Jun; 18(6):1307-13. PubMed ID: 2370181
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Health-related quality of life and voice following radiotherapy for laryngeal cancer--a comparison between glottic and supraglottic tumours.
    Tuomi L; Karlsson T; Johansson M; Finizia C
    Acta Oncol; 2015 Jan; 54(1):73-9. PubMed ID: 24914482
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dose, time, and fraction size issues for late effects in head and neck cancers.
    Taylor JM; Mendenhall WM; Lavey RS
    Int J Radiat Oncol Biol Phys; 1992; 22(1):3-11. PubMed ID: 1727126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glottic and supraglottic carcinoma: a retrospective comparison of radiotherapy alone with sandwich therapy in 366 patients.
    van Acht MJ; Hermans J; Dolsma WV; Hulshof JH; Leer JW
    Radiother Oncol; 1989 Feb; 14(2):103-12. PubMed ID: 2710942
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiotherapy as the primary approach in the treatment of laryngeal cancer.
    Jankovic I; Merkas Z
    Can J Otolaryngol; 1975; 4(5):919-26. PubMed ID: 1203798
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical study on laryngeal cancer].
    Ikarashi F; Nonomura N; Nakano Y
    Nihon Jibiinkoka Gakkai Kaiho; 1990 May; 93(5):772-8. PubMed ID: 2384832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patterns of fractionation for patients with T2N0M0 glottic larynx cancer undergoing definitive radiotherapy in the United States.
    Stokes WA; Stumpf PK; Jones BL; Blatchford PJ; Karam SD; Lanning RM; Raben D
    Oral Oncol; 2017 Sep; 72():110-116. PubMed ID: 28797446
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512).
    Trotti A; Zhang Q; Bentzen SM; Emami B; Hammond ME; Jones CU; Morrison WH; Sagar SM; Ridge JA; Fu KK; Ang KK
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):958-963. PubMed ID: 25035199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current status of radiation therapy--evidence-based medicine (EBM) of radiation therapy. Radiotherapy for pharyngeal and laryngeal cancer].
    Chatani M
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Mar; 62(4):126-31. PubMed ID: 12043214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does tumor control decrease by prolonging overall treatment time or interrupting treatment in laryngeal cancer?
    Van den Bogaert W; Van der Leest A; Rijnders A; Delaere P; Thames H; van der Schueren E
    Radiother Oncol; 1995 Sep; 36(3):177-82. PubMed ID: 8532903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.